CM
Cosmo Pharmaceuticals N.V.
CMOPF · OTC
$68.08 -4.60% (-$3.28)
1M -5.26%
Market Cap 1.02B €
P/E Ratio -
Div. Yield 3.57%
ROE 0.72%
Bulios Fair Price
$60.97
10.4% downside
Current Price
$68.08
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CMOPF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
19 /100
Expensive EV/EBITDA 410.50x
P/S 9.72x
P/B 2.11x
Growth
26 /100
Declining Rev. growth 0.88%
Book val. growth 1.78%
EPS growth N/A
Profitability
19 /100
Weak Gross margin 46.53%
Net margin 3.46%
FCF margin 15.12%
Quality
3 /100
Poor ROIC 6.79%
ROE 0.72%
Asset turnover 0.17x
Debt
80 /100
Low Debt/Equity 0.01x
Current ratio 7.18x
Net debt/EBITDA -21.88x
Stability
9 /100
Unstable Beta 1.49x
Rev. volatility 131.00%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CMOPF
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Giovanni di Napoli
Employees
324
Headquarters
Dublin
Upcoming events
24 MAR
Earnings
Upcoming earnings report